These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25974356)

  • 21. Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.
    Rambeau A; Gervais R; De Raucourt D; Babin E; Dugué AE; Florescu C; Blanchard D; Gery B
    Eur Arch Otorhinolaryngol; 2017 Jul; 274(7):2883-2889. PubMed ID: 28382396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skin Reaction to Cetuximab as a Criterion for Treatment Selection in Head and Neck Cancer.
    Strojan P; Zakotnik B; Žumer B; Karner K; Dremelj M; Jančar B; Jereb S; Grašič-Kuhar C
    Anticancer Res; 2018 Jul; 38(7):4213-4220. PubMed ID: 29970553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of allelic Variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab.
    Muñoz C; Caballero M; Hakim S; Verger E; Grau JJ
    Eur Arch Otorhinolaryngol; 2016 Aug; 273(8):2193-9. PubMed ID: 26245169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
    Ou D; Levy A; Blanchard P; Nguyen F; Garberis I; Casiraghi O; Scoazec JY; Janot F; Temam S; Deutsch E; Tao Y
    Oral Oncol; 2016 Aug; 59():50-57. PubMed ID: 27424182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience.
    Ock CY; Keam B; Lim Y; Kim TM; Lee SH; Kwon SK; Hah JH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
    Head Neck; 2016 Feb; 38(2):277-84. PubMed ID: 26104823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
    Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
    Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.
    Bonomo P; Loi M; Desideri I; Olmetto E; Delli Paoli C; Terziani F; Greto D; Mangoni M; Scoccianti S; Simontacchi G; Francolini G; Meattini I; Caini S; Livi L
    Crit Rev Oncol Hematol; 2017 Dec; 120():98-110. PubMed ID: 29198343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis.
    Korpics MC; Turchan WT; Koshy M; Spiotto MT
    Head Neck; 2022 Jul; 44(7):1528-1544. PubMed ID: 35393753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer.
    Lee KW; Koh Y; Kim SB; Shin SW; Kang JH; Wu HG; Sung MW; Keam B; Kim DW; Kim TM; Kim KH; Kwon TK; Hah JH; Kim IA; Ahn SH; Yoon DH; Lee SW; Kim SY; Nam SY; Jung KY; Baek SK; Hong SH; Lee SH; Heo DS
    Oncologist; 2015 Oct; 20(10):1119-20. PubMed ID: 26304911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
    Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of radiodermatitis associated with cetuximab in squamous cell carcinomas of the head and neck.
    Villavicencio M; Granados-García M; Vilajosana E; Domínguez-Cherit J
    Int J Dermatol; 2017 Jun; 56(6):602-609. PubMed ID: 28247918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis.
    Huang J; Zhang J; Shi C; Liu L; Wei Y
    BMC Cancer; 2016 Aug; 16(1):689. PubMed ID: 27565887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
    Xu T; Liu Y; Dou S; Li F; Guan X; Zhu G
    Oral Oncol; 2015 Sep; 51(9):875-9. PubMed ID: 26163437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
    Buiret G; Combe C; Favrel V; Pommier P; Martin L; Ecochard R; Fayette J; Tartas S; Ramade A; Céruse P
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):430-7. PubMed ID: 19775831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
    Fayette J; Bonnin N; Ferlay C; Lallemant B; Ramade A; Favrel V; Zrounba P; Chabaud S; Pommier P; Poupart M; Céruse P
    Anticancer Drugs; 2013 Jul; 24(6):623-9. PubMed ID: 23542750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study.
    Noronha V; Goswami C; Patil S; Joshi A; Patil VM; Murthy V; Arya S; Juvekar S; Goud S; Prabhash K
    J Laryngol Otol; 2016 Sep; 130(9):833-42. PubMed ID: 27456399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial.
    Habl G; Potthoff K; Haefner MF; Abdollahi A; Hassel JC; Boller E; Indorf M; Debus J
    BMC Cancer; 2013 Jul; 13():345. PubMed ID: 23855804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.